1. Home
  2. MBWM vs IOVA Comparison

MBWM vs IOVA Comparison

Compare MBWM & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mercantile Bank Corporation

MBWM

Mercantile Bank Corporation

HOLD

Current Price

$49.26

Market Cap

763.4M

Sector

Finance

ML Signal

HOLD

Logo Iovance Biotherapeutics Inc.

IOVA

Iovance Biotherapeutics Inc.

HOLD

Current Price

$2.21

Market Cap

968.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MBWM
IOVA
Founded
1997
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
763.4M
968.6M
IPO Year
1997
N/A

Fundamental Metrics

Financial Performance
Metric
MBWM
IOVA
Price
$49.26
$2.21
Analyst Decision
Buy
Buy
Analyst Count
4
12
Target Price
$52.88
$10.36
AVG Volume (30 Days)
63.6K
9.8M
Earning Date
01-20-2026
11-06-2025
Dividend Yield
3.09%
N/A
EPS Growth
6.26
N/A
EPS
5.27
N/A
Revenue
$233,714,000.00
$250,425,000.00
Revenue This Year
$10.44
$60.94
Revenue Next Year
$11.11
$60.85
P/E Ratio
$9.35
N/A
Revenue Growth
5.19
175.62
52 Week Low
$37.76
$1.64
52 Week High
$51.89
$8.56

Technical Indicators

Market Signals
Indicator
MBWM
IOVA
Relative Strength Index (RSI) 68.90 46.56
Support Level $46.94 $2.18
Resistance Level $47.77 $2.32
Average True Range (ATR) 0.99 0.12
MACD 0.35 -0.01
Stochastic Oscillator 93.08 18.11

Price Performance

Historical Comparison
MBWM
IOVA

About MBWM Mercantile Bank Corporation

Mercantile Bank Corp operates as a bank holding company. It offers various commercial banking services to individuals, businesses, governmental units, and other institutions. These services include deposit products such as checking, savings, and term certificate accounts and lending products such as commercial, residential mortgage, and installment loans. The company generates revenue from interest and dividends earned on loans, securities, and other financial instruments.

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Share on Social Networks: